Free tool
FAERS Monitor: Adempas
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204819 or its brand name (Adempas, Riociguat). Reports on generic versions are filed under their own applications.
Reports
32,879
Serious
25,172
77% of reports
Hospitalization
15,491
Death reported
7,129
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea5,794
- death5,421
- headache4,575
- nausea3,819
- dizziness3,589
- diarrhoea3,574
- hypotension3,452
- fatigue3,021
- hospitalisation2,326
- vomiting2,147
- cough1,827
- oedema peripheral1,802
- pneumonia1,781
- fluid retention1,769
- malaise1,689
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 50 |
| 2014 | 837 |
| 2015 | 1,491 |
| 2016 | 2,606 |
| 2017 | 2,909 |
| 2018 | 3,297 |
| 2019 | 3,075 |
| 2020 | 3,101 |
| 2021 | 2,953 |
| 2022 | 2,850 |
| 2023 | 2,902 |
| 2024 | 3,038 |
| 2025 | 2,363 |
| 2026 | 1,393 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,280 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fluid retentionSignal | 1,769 | 23.0 | 22.0 | 36,024 |
| hypotensionSignal | 3,452 | 11.2 | 10.8 | 31,753 |
| hospitalisationSignal | 2,326 | 9.8 | 9.4 | 18,266 |
| oedema peripheralSignal | 1,802 | 9.6 | 9.2 | 13,720 |
| dyspnoeaSignal | 5,794 | 6.6 | 6.5 | 28,024 |
| headacheSignal | 4,575 | 4.7 | 4.6 | 13,609 |
| dizzinessSignal | 3,589 | 4.6 | 4.5 | 10,381 |
| coughSignal | 1,827 | 4.2 | 4.0 | 4,462 |
| deathSignal | 5,421 | 4.0 | 3.9 | 12,869 |
| diarrhoeaSignal | 3,574 | 3.6 | 3.4 | 6,734 |
| pneumoniaSignal | 1,781 | 3.5 | 3.4 | 3,264 |
| nauseaSignal | 3,819 | 3.1 | 3.0 | 5,605 |
| vomitingSignal | 2,147 | 2.9 | 2.8 | 2,777 |
| fatigueSignal | 3,021 | 2.5 | 2.4 | 2,779 |
| malaiseSignal | 1,689 | 2.5 | 2.4 | 1,501 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.